RT-PCR detection of cryptic rearrangements of CBF␤-MYH11. excessive DNA contamination of RNA samples, inadequate stringency of annealing conditions or the use of excessive rounds of amplification. Regardless of the precise cause, the publication by Hackwell et al 9 emphasises the need to verify the identity of PCR products, particularly when there are apparent discrepancies between cytogenetic and molecular findings.
in seven (7.6%) of 92 adult patients with myelodysplastic syndrome (MDS) and AML with trilineage myelodysplasia, 4 but in none of 20 patients with chronic myelogenous leukemia (CML) 5 or 50 patients with acute lymphoblastic leukemia (ALL). The patients with this duplication have been associated with hyperleukocytosis 3 and a poor prognosis. 6 In childhood hematological malignancies, we found the tandem duplication of the FLT3 gene in 12 (13.8%) of 87 AML patients, all of whom died within 47 months. We also found two (4%) of 50 ALL patients who had mixed lineage phenotype, but none among patients with MDS or juvenile chronic myelogenous leukemia (JCML).
7 There were, however, no reports of FLT3 duplication in infant leukemia. Here, we examined tandem duplication of the FLT3 gene in infant acute leukemia, which is known to often have myeloid phenotype and a poor prognosis. 8 One hundred and eight infant acute leukemia patients under 1 year of age including 23 with AML, 82 with ALL, and three with acute mixed lineage leukemia according to the French-American-British (FAB) classification were examined in this study. Cytogenetic analysis of these infant leukemia patients demonstrated various abnormal karyotypes, including 32 patients with t(4;11) (q21; q23), 14 patients with t(11;19)(q23;p13), six patients with t(9;11)(p22;q23), five patients with other 11q23 translocations, and 20 patients with other chromosomal abnormalities. Eleven patients were judged as having normal chromosomes and 20 patients as having unknown karyotype. Among them, MLL gene rearrangement was found in 66 (64.1%) of 103 patients examined, including 14 AML, 50 ALL, and two mixed lineage leukemia patients.
High molecular weight DNA was extracted from fresh samples from the above 108 patients using the proteinase-K phenol-chloroform method.
7 One hundred nanograms (ng) of genomic DNA was amplified in a total volume of 50 l of reaction mixture. 7 Genomic PCR was performed with primers of the 11F and 11R combination 2 which was located at exon 11 as described in a previous study. The sequences of the primers used are as follows: 11F (sense), 5Ј-CAATTTAGGTATGAAAGCC-3Ј; 11R (antisense), 5Ј-CAAACTCTAA ATTTTCTCT-3Ј. Ten l of the amplified PCR products were electrophoresed on a 3% agarose gel, stained with ethidium bromide, and photographed with a polaroid camera under UV light. Abnormal PCR product was cloned into a TA cloning vector, and then subjected to sequencing 7 with primers T7 and M13-Reverse, using the Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Urayasu, Japan) on an Applied Biosystems DNA sequencer (model ABI 310).
The tandem duplication of the FLT3 gene was found in only one (4.3%) of 23 AML patients by genomic PCR (Figure 1 ). Sequence analysis of this one sample revealed a tandem duplication of 19 bp (nt 1777ෂ1795) with a 2 bp insertion within exon 11 (Figure 1 ). This AML patient with the duplication was a 9-month-old boy, and had FAB-M4Eo morphology (17% bone marrow eosinophil) with karyotype of 46, XY, inv(16)(p13q23). He was treated by AML-oriented therapy but relapsed 6 months after diagnosis. Then, he received a CD34-positive transplant from his mother but died 1 month later. The duplication was not found in 82 infant ALL patients or three acute mixed lineage leukemia patients. Notably, 66 infant acute leukemia patients with MLL gene rearrangement, including 50 ALLs and 14 AMLs, had no duplication.
Recently, tandem duplication within JM/TK-1 domains was reported in 17ෂ20% of adult AML patients and 12.3% of childhood AML patients. 7 However, in our present study, the tandem duplication was found in only one (4.3%) of 23 infant AML patients. Thus, the frequency of duplication in infant AML was lower than that in adult and childhood AML patients reported to date. 2, 6, 7 The reason why there was a close relationship between age and the duplication is unknown. One possibility is that about half of the infant AML had MLL rearrangements, which might not be associated with the FLT3 duplication. No tandem duplications of the FLT3 gene were detected in 82 infant ALL patients, including 50 patients with MLL gene rearrangements in this study. Notably, 66 infant leukemia patients with MLL gene rearrangement had no duplication. The one AML patient with the duplication died within 7 months of diagnosis. These results suggest that tandem duplication is rarely involved in infant AML, but not in infant ALL, and that infant AML patients with the duplication may have a poor prognosis, although inv(16) is usually considered to be a biologically good prognostic factor. These findings of infant acute leukemia are compatible with those of childhood and adult acute leukemia. 
Loss of CD38 antigen on CD34
؉ CD38 ؉ cells during short-term culture
TO THE EDITOR
The earliest progenitor in the hierarchy of hematolymphopoietic cells, the hematopoietic stem cell (HSC), can repopulate the bone marrow after transplantation and sustain hematopoiesis, generating all known mature blood cells. Assay systems to measure repopulating capacity of HSCs in humans are not available. However, early progenitors can be detected by their ability to produce cobble stone areas (CAFC), and colony-forming cells (CFC) for at least 5 weeks on stroma (LTC-IC). In addition, the repopulating capacity of human HSCs can be measured in mice with severe combined immunodeficiency (SRC).
Several surface antigens such as CD34, CD38, and HLA DR have been used as markers to enrich HSC from different sources. 1 However, even the most highly enriched populations still remain heterogeneous. A more than 1000-fold enrichment of SRC and LTC-IC was found in CD34 +
CD38
− cells compared with unseparated mononuclear cells from cord blood or bone marrow.
2,3 Here, we studied whether after ex vivo culture CD38 still remains a marker for more differentiated progenitor cells.
Cord blood CD34 + hematopoietic progenitor cells were purified by the MACS progenitor isolation kit (Miltenyi Biotec, Bergish Gladbach, Germany) and cultured for 4 days. The effect of two different growth factor combinations on the expression of CD34 and CD38 was analyzed. Cells were either cultured in BIT medium supplemented with Flt-3 ligand (FL, 100 ng/ml), stem cell factor (SCF, 100 ng/ml), and interleukin-3 (IL-3, 20 ng/ml, or with IL-1␤ (3 ng/ml), SCF (10 ng/ml), and Il-3 (20 ng/ml, cytokines were obtained from TeBu, Frankfurt a.M., Germany). These conditions were previously shown to expand LTC-IC and CD34 + cells, respectively. 4, 5 On day 4, cells were stained with anti-CD34 and anti-CD38 (antibodies were obtained from Pharmingen, San Diego, CA, USA) and analyzed on a FACScalibur (Becton Dickinson, Heidelberg, Germany). Before culture, 95% of the cells were CD34
+ (Figure 1a ). After culture in SCF, IL-3 and IL-6, most cells still remained CD38
+ and 21% had lost the CD34 antigen (Figure 1c) . In contrast, cells cultured in FL, SCF and IL-3 mostly retained the CD34 antigen and 31% had become CD34 We then determined whether the initial staining of cells for FACS sorting with anti-CD38 directly after isolation interfered with CD38 antigen detection on day 4. Directly after MACS purification, half the cells were stained with anti-CD38 conjugated with fluorescein and then cultured for 4 days with FL, IL-3 and SCF. The remaining cells were cultured directly as a control. On day 4, both populations (prestained and directly cultured) were stained with anti-CD38 cychrome and analyzed by flow cytometry. No difference in the intensity of anti-CD38 staining was seen (data not shown).
Finally, we tested whether the CD34 + CD38 − cells that arose after culture were enriched for cells of specific lineages. CD34 +
+ cells were sorted, cultured for 4 days and then stained with CD34, CD38, and with antibodies against specific lineage antigens. The results of the three-color flow cytometric analysis are shown in Table 1 . On CD34 + CD38 − cells no significant staining was seen with antibodies against B cell, T cell, or dendritic markers. A low percentage expressed Glycophorin-A and myeloid antigens (CD33, CD14, CD16) were found on approximately half of the day 4 CD34 +
− cells. These results show that although within the CD34 +
− cells there is a population with myeloid potential, a considerable number of cells is negative for standard lineage markers.
In conclusion, the CD34 + CD38 − Lin − cells that arose from a CD34 + CD38 + population during culture have a phenotype normally found on early hematopoietic progenitors directly after isolation. However, functional studies, such as LTC-IC and SRC assays will be necessary to clarify whether this population is indeed enriched in HSC, or whether the CD38 antigen is not a reliable indicator of differentiation after ex vivo culture.
